China Advances AI-Driven Drug Development Amid Self-Reliance Push

China is intensifying its support for artificial intelligence (AI)-driven drug developers as part of a broader initiative to achieve technological self-reliance. This effort is exemplified by the funding of Hangzhou-based METiS TechBio, which has made significant strides in AI-designed therapies. In August 2022, METiS secured 400 million yuan (approximately US$60 million) in Series D financing, led by state-backed entities including the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund. This funding is part of a larger trend where state-linked investors are increasingly backing innovative biotech firms.

South China Morning Post

Founded in 2020, METiS TechBio has developed MTS-004, an oral treatment for neurological disorders, which has successfully completed Phase III clinical trials. This milestone marks MTS-004 as China's first AI-designed drug candidate to reach this advanced stage of development. The company is now preparing to seek regulatory approval in China within the current year. METiS's proprietary AI platform focuses on optimizing drug delivery, showcasing the potential of AI in revolutionizing pharmaceutical development.

South China Morning Post

In addition to the recent Series D financing, METiS raised approximately US$150 million in earlier funding rounds throughout 2022. This funding came from a diverse array of domestic investors, including state-linked insurers such as PICC Capital and China Life Private Equity, as well as venture firm HongShan. Looking ahead, METiS is contemplating an initial public offering (IPO) in Hong Kong, which could potentially raise an additional US$200 million, according to a Bloomberg report from May 2023.

South China Morning Post

While the push for AI in drug development is gaining momentum, some critics express concerns regarding the reliance on state-backed funding and the implications for innovation in the private sector. They argue that such heavy government involvement may stifle competition and lead to inefficiencies in the market.

South China Morning Post

Officials from the Beijing Medical and Health Industry Investment Fund have emphasized the importance of supporting domestic biotech firms to enhance China's self-reliance in healthcare technology. They assert that investments in AI-driven drug development are crucial for advancing the country's pharmaceutical capabilities.

South China Morning Post

As METiS TechBio seeks regulatory approval for MTS-004 and considers its IPO, the outcomes of these developments will be closely monitored as indicators of China's progress in achieving technological self-reliance in the pharmaceutical sector.

South China Morning Post